PolyNovo Limited

Equities

PNV

AU000000PNV0

Medical Equipment, Supplies & Distribution

Delayed Australian S.E. Other stock markets 08:20:17 24/05/2024 am IST			5-day change	1st Jan Change
2.08 ^AUD	+2.46%		0.00%	+25.68%

08/05	PolyNovo's Revenue Climbs 68.6% in April	MT
04/03	Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace	MT

Polynovo Limited Provides Sales Guidance for the Quarter Ended June 2020; Provides Sales Guidance for the Full Year 2020

July 10, 2020 at 04:55 am IST

PolyNovo Limited repeats earlier guidance that product sales for fiscal year 2020 are likely to at least double fiscal year 2019. Sales for the June quarter were 33% greater than the March quarter, but this includes a record US result for June 2020.

Latest news about PolyNovo Limited

PolyNovo's Revenue Climbs 68.6% in April	08/05	MT
Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace	04/03	MT
Transcript : PolyNovo Limited, H1 2024 Earnings Call, Feb 27, 2024	27/02
PolyNovo Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
PolyNovo Secures Largest Single Order Worth AU$1.2 Million; Shares Rise 3%	16/02	MT
PolyNovo Logs Record Monthly Sales in November	06/12	MT
PolyNovo Limited Reports Unaudited Sales Results for the Month of November 2023	06/12	CI
Transcript : PolyNovo Limited - Shareholder/Analyst Call	03/11
Polynovo Secures Additional Funding from BARDA for Burn Treatment Trial	02/23/02	MT
Transcript : PolyNovo Limited, 2023 Earnings Call, Aug 23, 2023	23/23/23
PolyNovo Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23/23/23	CI
Immuron Appoints Paul Brennan as Board Chairman	30/23/30	MT
PolyNovo Limited Reports Revenue Results for the Month and Nine Months Ended 31 March 2023	02/23/02	CI
PolyNovo Limited(ASX:PNV) added to S&P/ASX 200 Index	20/23/20	CI
Polynovo Swings to Net Loss in Fiscal H1 on Employee, R&D Expansion; Shares Fall 4%	24/23/24	MT
Transcript : PolyNovo Limited, H1 2023 Earnings Call, Feb 23, 2023	23/23/23
PolyNovo Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23/23/23	CI
PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial	15/23/15	CI
Transcript : PolyNovo Limited - Shareholder/Analyst Call	17/23/17
PolyNovo Limited Provides Unaudited Revenues Results for the First Half 2023	16/23/16	CI
Transcript : PolyNovo Limited Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 07:30 AM	11/23/11
Polynovo to Raise AU$20 Million from Share Purchase Plan	16/22/16	MT
Transcript : PolyNovo Limited - Pre Recorded Special Call	05/22/05
Polynovo Kicks Off $11 Million Share Offering	30/22/30	MT
PolyNovo to Raise $20 Million in Institutional Placement; Shares Slip 9%	23/22/23	MT

Chart PolyNovo Limited

Duration

Period

More charts

Company Profile

PolyNovo Limited is an Australia-based company, which is engaged in the development of medical devices for various medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM product is designed to help surgeons treat traumatic wounds. NovoSorb BTM may be used to temporarily close the wound and aid the body in generating new tissue. It is indicated for full or deep partial-thickness burns, surgical and reconstructive wounds and traumatic wounds. BTM is applied to a wound once the unhealthy or dead tissue has been surgically removed. NovoSorb is a medical-grade polymers that can be expressed in a range of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

22/08/2024 - Q4 2024 Earnings Release (Projected)

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for PolyNovo Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.03 AUD

Average target price

2.113 AUD

Spread / Average Target

+4.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
POLYNOVO LIMITED	+25.68%	944M
ABBOTT LABORATORIES	-5.31%	182B
MEDTRONIC PLC	-1.21%	114B
BECTON, DICKINSON AND COMPANY	-5.53%	67.76B
DEXCOM, INC.	+1.22%	51.91B
CENCORA, INC.	+7.03%	43.23B
HOYA CORPORATION	+5.28%	41.07B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.96%	32.07B
TERUMO CORPORATION	+14.65%	25B
ZIMMER BIOMET HOLDINGS, INC.	-4.81%	24.55B

Other Medical Equipment, Supplies & Distribution